Trial Profile

A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 22 Sep 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pacritinib (Primary)
Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myelofibrosis
Focus Adverse reactions; Therapeutic Use
Sponsors S*BIO

Most Recent Events

10 Dec 2013 Pooled analysis assessing outcomes in patients with no more than 100,000 platelets/microL at baseline presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
28 Jun 2013 Pooled safety results of this trial and 3 other phase I and II trials will be presented at the 18th Congress of the European Hematology Association in June 2013. Results also published in a Cell Therapeutics media release.
19 Apr 2012 Actual end date Jan 2012 added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com